osteoarthritis

obesity overweight weight loss weigh
Biotech

Lilly's obesity triple threat tops phase 3 efficacy forecasts

Lilly linked its triple agonist to 28.7% weight loss and a 75.8% reduction in pain scores in patients with obesity and knee osteoarthritis.
Nick Paul Taylor Dec 11, 2025 8:15am
Red stop sign on road

Eli Lilly sidelines pain prospect in another pipeline shift

Oct 30, 2025 2:19pm
Broom sweep clean

Novartis axes osteoarthritis asset and radioligand therapy

Apr 29, 2025 5:24am
X ray illustration of a running person with pain in knee joint with blue background

Novartis culls ph. 2 knee pain trial testing anti-ADAMTS-5 asset

Apr 16, 2025 2:55pm
In Laboratory Over the Shoulder View of Scientist in Protective Clothes Doing Research on a Personal Computer

GSK pays AI biotech $45M upfront to identify fibrotic targets

Dec 10, 2024 4:59am
knee x-ray

Levicept's ex-Pfizer drug reduces osteoarthritis pain in ph. 2

Aug 6, 2024 1:00am